Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SAFC, a member of the Sigma-Aldrich group, has announced its plans for a $12 million expansion at its niche biologics production facility in Carlsbad, California.
Subscribe to our email newsletter
Two new fully segregated state-of-the-art viral product manufacturing suites will be built to employ the latest in disposable bioreactor technologies and enable SAFC Pharma’s viral manufacturing to increase to commercial-scale quantities.
The expansion will add to the current 44,000 sq. ft. site and be Biosafety Level 2 compliant, allowing manipulation of human pathogens. Due to become operational in the second half of 2009, the new suites will add 8,000 sq. ft. of manufacturing space and enable 100 L batch production in stirred tank bioreactors and 1,000 L batch manufacturing in disposable bioreactors.
David Feldker, vice president of manufacturing and US Operations, SAFC Pharma, said: “This expansion will increase our Carlsbad site capabilities from clinical-scale to commercial-scale manufacturing, further demonstrating SAFC’s continued commitment to support its customers in the development and manufacturing of complex chemistries and niche biologics.”